Lidbree (Lidocaine)

Lidocaine works by reversibly blocking voltage‑gated sodium channels on nerve membranes. This inhibition stops the rapid influx of sodium ions needed for depolarisation, preventing the generation and spread of pain signals. In the uterus, the effect is confined to the site of application, producing localized loss of sensation.

The appropriate dose of Lidbree is determined by the prescribing clinician based on the specific procedure, patient characteristics, and institutional protocols. Dosage recommendations are not publicly disclosed and should be obtained from the treating physician or the product’s prescribing information.

Safety data for intrauterine lidocaine during pregnancy and lactation are limited. Use is generally reserved for situations where the benefit outweighs potential risk, and it should be administered under close medical supervision. Breastfeeding mothers should consult their healthcare provider before use.

To order Lidbree, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including cold‑chain where applicable) and assists with import documentation.

Lidbree contains lidocaine, an amide‑type local anesthetic with a rapid onset and moderate duration. Compared with bupivacaine, another intrauterine anesthetic, lidocaine acts faster but has a shorter duration of analgesia. Choice between agents depends on procedural length, desired onset time, and patient‑specific safety considerations.

Lidbree should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations. Follow any additional handling instructions provided by the manufacturer to maintain sterility and potency.

Lidbree is administered via intrauterine injection. After aseptic preparation, the solution is introduced into the uterine cavity using a suitable catheter or syringe, allowing the anesthetic to diffuse locally. Administration is performed by trained healthcare professionals following standard procedural protocols.

Serious risks include systemic toxicity such as cardiac arrhythmias, central nervous system effects like seizures, severe allergic reactions (anaphylaxis), and rare cases of methemoglobinemia. Prompt recognition of symptoms and immediate medical intervention are essential to mitigate these potentially life‑threatening events.

Lidbree should be avoided in patients with known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe hepatic impairment, and individuals with pre‑existing cardiac conduction abnormalities or uncontrolled arrhythmias. Contraindications must be confirmed by the prescribing clinician before administration.